Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Bergenbio ASA
BGBIOCurrent price
7.74 NOK
-0.17 NOK (-2.12%)
Last closed
7.91 NOK
Company
www.bergenbio.com
ISIN
NO0010650013
Sector
Healthcare
Industry
Biotechnology
Exchange
Oslo Stock Exchange
Capitalization
355 117 661 NOK
Yield for 12 month
-57.37 %
1Y
3Y
5Y
10Y
15Y
BGBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway. Address: Møllendalsbakken 9, Bergen, Norway, 5009
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
219.1 NOKP/E ratio
–Dividend Yield
–Current Year
+352 725 NOK
Last Year
+387 606 NOK
Current Quarter
–
Last Quarter
+166 399 NOK
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures BGBIO
1 year
3 years
5 years
10 years
EBITDA
-161 358 900 NOK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-44.17 %
PEG Ratio
–
Return On Equity TTM
-85.55 %
Wall Street Target Price
219.1 NOK
Revenue TTM
519 130 NOK
Book Value
4.47 NOK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-9 %
Dividend Yield
–
Gross Profit TTM
387 604 NOK
Earnings per share
-15.11 NOK
Diluted Eps TTM
-15.11 NOK
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BGBIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BGBIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:100
Payout Ratio
–
Last Split Date
30.05.2024
Dividend Date
–
Stock Valuation BGBIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
422.9648
Price Sales TTM
684.0624
Enterprise Value EBITDA
-1.103
Price Book MRQ
1.9269
Financials BGBIO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BGBIO
For 52 weeks
8.26 NOK
35.67 NOK
50 Day MA
9.95 NOK
Shares Short Prior Month
–
200 Day MA
14.74 NOK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart